Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Gains from Sales and Divestitures (2020 - 2025)

Tango Therapeutics (TNGX) has 5 years of Gains from Sales and Divestitures data on record, last reported at $480077.0 in Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 84.03% year-over-year to $480077.0; the TTM value through Dec 2025 reached $480077.0, up 84.03%, while the annual FY2025 figure was $480077.0, 84.03% up from the prior year.
  • Gains from Sales and Divestitures reached $480077.0 in Q4 2025 per TNGX's latest filing, up from $454414.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $480077.0 in Q4 2025 and bottomed at $37500.0 in Q2 2023.
  • Average Gains from Sales and Divestitures over 4 years is $255024.5, with a median of $256385.0 recorded in 2021.
  • Peak YoY movement for Gains from Sales and Divestitures: tumbled 67.45% in 2021, then soared 595.64% in 2024.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $256598.0 in 2021, then tumbled by 85.39% to $37500.0 in 2023, then skyrocketed by 595.64% to $260865.0 in 2024, then skyrocketed by 84.03% to $480077.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $480077.0 in Q4 2025, $454414.0 in Q3 2025, and $433483.0 in Q2 2025.